Who are Arimidex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kisqali, Exemestane and GnRH analogue, Ovarian Function Suppression + Aromatase Inhibitor, Aromasin, Femara, LETROZOLE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anastrozole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Arimidex — Competitive Intelligence Brief

Arimidex (anastrozole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor. Area: Oncology.

marketed Aromatase inhibitor Aromatase enzyme Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arimidex (anastrozole) — AstraZeneca. Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arimidex TARGET	anastrozole	AstraZeneca	marketed	Aromatase inhibitor	Aromatase enzyme	1995-12-27
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Exemestane and GnRH analogue	Exemestane and GnRH analogue	GBG Forschungs GmbH	phase 3	Aromatase inhibitor + GnRH agonist combination	Aromatase enzyme; GnRH receptor
Ovarian Function Suppression + Aromatase Inhibitor	Ovarian Function Suppression + Aromatase Inhibitor	NRG Oncology	phase 3	Combination endocrine therapy (GnRH agonist/antagonist + aromatase inhibitor)	GnRH receptor (ovarian suppression component) and aromatase enzyme (AI component)
Aromasin	exemestane	Pfizer	marketed	Aromatase Inhibitor [EPC]	Aromatase	1999-01-01
Femara	letrozole	Novartis AG	marketed	Aromatase Inhibitor [EPC]	Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial	1997-07-25
LETROZOLE	LETROZOLE		marketed	Aromatase Inhibitor [EPC]		1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor class)

AstraZeneca · 4 drugs in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 2 drugs in this class
Eastern Virginia Medical School · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Gynaecologisch Oncologisch Centrum Zuid · 1 drug in this class
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · 1 drug in this class
IVI Madrid · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Lumara Health, Inc. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arimidex — Competitive Intelligence Brief. https://druglandscape.com/ci/anastrozole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab